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However, among premenopausal patients, trial conclusions 
drawn from PgR status differed — immunohistochemically 
determined PgR status could predict response to endocrine 
therapy, unlike that determined by the extraction assay. 
[J Natl Cancer Inst 2006;98: 1571 – 81 ] 
 The levels of estrogen receptor (ER) and progesterone recep-
tor (PgR) in the primary tumor of a patient with early-stage 
 invasive breast cancer are powerful predictors of that patient’s 
response to adjuvant endocrine therapies and chemosensitivity of 
the primary tumor  ( 1 – 3 ) . The 2005 International Expert  Consensus 
on the Primary Therapy of Early Breast Cancer  recognized that 
endocrine responsiveness of the primary tumor should be the fi rst 
consideration for selecting adjuvant systemic therapies  ( 4 ) . 
 Early studies establishing the predictive and prognostic value 
of steroid hormone receptors measured levels of ER and PgR in 
 Background: Tumor levels of steroid hormone receptors, a 
factor used to select adjuvant treatment for early-stage breast 
cancer, are currently determined with immunohistochemical 
assays. These assays have a discordance of 10% – 30% with 
previously used extraction assays. We assessed the concor-
dance and predictive value of hormone receptor status as 
determined by immunohistochemical and extraction assays 
on specimens from International Breast Cancer Study Group 
Trials VIII and IX. These trials predominantly used extrac-
tion assays and compared adjuvant chemoendocrine therapy 
with endocrine therapy alone among pre- and postmeno-
pausal patients with lymph node – negative breast cancer. 
Trial conclusions were that combination therapy provided a 
benefi t to pre- and postmenopausal patients with estrogen 
receptor (ER) – negative tumors but not to ER-positive post-
menopausal patients. ER-positive premenopausal patients 
required further study.  Methods: Tumor specimens from 571 
premenopausal and 976 postmenopausal patients on which 
extraction assays had determined ER and progesterone 
receptor (PgR) levels before randomization from October 1, 
1988, through October 1, 1999, were re-evaluated with an 
immunohistochemical assay in a central pathology labora-
tory. The endpoint was disease-free survival. Hazard ratios of 
recurrence or death for treatment comparisons were esti-
mated with Cox proportional hazards regression models, and 
discriminatory ability was evaluated with the  c index. All sta-
tistical tests were two-sided.  Results: Concordance of hor-
mone receptor status determined by both assays ranged from 
74% ( κ = 0.48) for PgR among postmenopausal patients to 
88% ( κ = 0.66) for ER in postmenopausal patients. Hazard 
ratio estimates were similar for the association between 
 disease-free survival and ER status (among all patients) or PgR 
status (among postmenopausal patients) as determined by 
the two methods. However, among premenopausal patients 
treated with endocrine therapy alone, the discriminatory 
ability of PgR status as determined by immunohistochemical 
assay was statistically signifi cantly better ( c index = 0.60 ver-
sus 0.51;  P = .003) than that determined by extraction assay, 
and so immunohistochemically determined PgR status could 
predict disease-free survival.  Conclusions : Trial conclusions 
in which ER status (for all patients) or PgR status (for post-
menopausal patients) was determined by immunohistochem-
ical assay supported those determined by extraction assays. 
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tumor cytosols with extraction assays  ( 5 ) . Over the past 30 
years, when the importance of evaluating steroid hormone re-
ceptor levels was being established and when the need to assess 
the value of adjuvant therapies according to receptor level in 
clinical trials was being recognized, the standard method of 
 determining hormone receptors changed from extraction assays 
to immuno histochemical assays. This change was brought about 
by the development of immunohistochemical assays in general, 
followed by the wide commercial availability of ER antibodies 
and PgR antibodies in the 1990s. Immunohistochemical assays 
are less labor intensive and less expensive than extraction 
 assays. They are also suitable for small tumors, allow morpho-
logic correlation, and can be used on retrospectively collected 
specimens. 
 When hormone receptor status of tumor tissue determined by 
immunohistochemical assay has been compared with that deter-
mined by extraction assays  ( 6 – 10 ) , discordance of 10% – 30% has 
been found for both ER and PgR status. There has been remark-
able consistency in this discordance across the literature, espe-
cially when one considers that previous studies were predominantly 
cohort studies, in which patient cohorts varied widely across and 
within studies (e.g., by disease stage and characteristics, treat-
ments received, age, and menopausal status), and that assay 
methods varied widely (e.g., type of tissue and tissue preparation, 
type of extraction assays, antibodies used in the immunohisto-
chemical assay, and scoring and cut points used to classify tu-
mors as negative or positive)  ( 6 – 14 ) . 
 Hormone receptor status determined by immunohistochemi-
cal assay has also been found consistently to have similar or su-
perior predictive and prognostic value than that determined by 
extraction assays  ( 6 , 7 , 14 – 16 ) . It is important to note, however, 
that many of these studies were limited by short follow-up 
and that the predictive and prognostic value was confounded by 
the inclusion in the cohort of women treated with a range of 
 therapies  ( 11 ) . 
 We therefore decided to use specimens from well-defi ned ran-
domized clinical trial cohorts to investigate the extent to which 
the method of assessing hormone receptor status may affect trial 
conclusions. The clinical trials that we selected were two Interna-
tional Breast Cancer Study Group (IBCSG) randomized clinical 
trials of adjuvant therapy in pre- and perimenopausal patients 
(Trial VIII) and in postmenopausal patients (Trial IX) with lymph 
node – negative breast cancer. In such patients, the receipt of che-
motherapy in addition to endocrine therapy is highly dependent 
on hormone receptor status. IBCSG Trial VIII concluded that 
premenopausal women with ER-negative (i.e., endocrine non-
responsive), lymph node – negative breast cancer should receive 
adjuvant chemotherapy, whereas for patients with ER-positive 
(i.e., endocrine responsive) disease, the combination of chemo-
therapy with ovarian function suppression or other endocrine 
agents and the use of endocrine therapy alone should be studied 
further  ( 17 ) . IBCSG Trial IX concluded that postmenopausal pa-
tients with lymph node – negative breast cancer benefi ted substan-
tially from adjuvant chemotherapy if their cancer was ER negative 
(i.e., endocrine nonresponsive); in contrast, if their cancer was 
ER positive (i.e., endocrine responsive), they obtained no benefi t 
from the combination treatment compared with endocrine ther-
apy alone  ( 18 ) . 
 We investigated the concordance of hormone receptor status 
as determined by extraction assays originally in local pathol-
ogy offi ces when patients were randomly assigned to treatment 
and as determined, more recently, by immunohistochemical as-
say in the IBCSG Central Pathology Laboratory. We examined 
the extent to which the assessment of treatment responsiveness 
in the two  randomized trials differed when ER status was de-
termined by immunohistochemical assay and by extraction 
 assays. We further examined the assessment of treatment re-
sponsiveness according to PgR status, which was not consid-
ered in the primary trial analyses, because, in particular, we 
wanted to clarify whether PgR status as determined by either 
assay could predict treatment responsiveness. PgR requires a 
more technically diffi cult extraction assay than that for ER, and 
the PgR level in the primary tumor has been discounted by 
some as not useful in clinical practice  ( 19 ) , although it has been 
endorsed by others as supplementing information on ER level 
 ( 20 – 22 ) . 
 P ATIENTS AND M ETHODS 
 Trial Cohorts 
 The designs of IBCSG Trials VIII  ( 17 ) and IX  ( 18 ) have been 
described. Briefl y, Trial VIII enrolled pre- and perimenopausal 
patients with lymph node – negative breast cancer. The trial evalu-
ated whether sequential treatment with six 28-day courses of 
classical chemotherapy with cyclophosphamide, methotrexate, 
and fl uorouracil (CMF) followed by 18 monthly subcutaneous 
implants of the gonadotropin-releasing hormone analog gosere-
lin was statistically signifi cantly associated with longer disease-
free survival than six 28-day courses of classical CMF 
chemotherapy alone or 24 monthly implants of goserelin alone. 
From March 1, 1990, through October 1, 1999, a total of 1063 
assessable patients were randomly assigned to treatment. Trial IX 
enrolled postmenopausal patients with lymph node – negative 
breast cancer and evaluated whether sequential treatment with 
three 28-day courses of classical CMF chemotherapy followed 
by tamoxifen for 57 months was associated with statistically sig-
nifi cantly longer disease-free survival than tamoxifen alone for 
60 months. From October 1, 1988, through August 1, 1999, a 
total of 1669 eligible and assessable patients were randomly 
 assigned to treatment. Previously reported trial results were 
 presented according to CONSORT guidelines and included par-
ticipant fl ow diagrams  ( 17 , 18 ) . Institutional review boards re-
viewed and approved the protocols, and informed consent was 
required according to the criteria established within the individ-
ual countries. 
 In both trials, patients with ER-positive, ER-negative, or ER-
unknown tumors (ER-unknown status was allowed only if ER 
determination was not possible because of the lack of tumor ma-
terial) were eligible until August 1, 1998. At that time, protocol 
amendments restricted enrollment to patients with ER-positive 
tumors because other trials had found that, for patients with ER-
negative tumors, tamoxifen was not effective and ovarian abla-
tion also might not be effective  ( 23 , 24 ) . More than 94% of 
patients in these two trials were randomly assigned to treatment 
before release of the amendments. Randomization was stratifi ed 
according to ER status and Trial IX was statistically powered for 
subset analyses according to ER status (the entire trial cohort had 
80% power to detect a relative reduction in relapse risk of 
33% for the ER-positive stratum and 50% for the ER-negative 
stratum). 
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 Pathology Methods 
 Before randomization in both trials, concentrations of steroid 
hormone receptor in the primary tumors were determined by lo-
cal pathologists with the use of standard assay methods  ( 25 , 26 ) . 
At the trials’ outset, ER status was determined by extraction as-
says, including a sucrose-gradient, dextran-coated charcoal assay 
or an enzyme-linked immunosorbent assay (ELISA); determina-
tion of ER status by immunohistochemical assay was allowed 
later in the study. A case report form collected data about all 
available quantitative and qualitative results from steroid hor-
mone receptor assays. In Trials VIII and IX, 65% and 71% of 
patients, respectively, had their hormone receptor levels deter-
mined by an extraction assay. The assay method used was 
 dextran-coated charcoal assay or ELISA in approximately 55% 
and 45% of these patients, respectively. 
 More than 80% of patients randomly assigned to treatment in 
Trials VIII and IX had archival tumor material available for im-
munohistochemical hormone receptor evaluation. Retrospective 
tissue collection was carried out in accordance with institutional 
guidelines and national laws. Immunohistochemical assays of 
the expression of ER and PgR in the primary tumors were carried 
out at the IBCSG Central Pathology Laboratory in Milan, Italy, 
in a blinded manner, as previously described  ( 27 ) . Tumor speci-
mens of 571 premenopausal and 976 postmenopausal patients 
on which extraction assays had determined ER and PgR levels 
before patients were randomly assigned to treatment were re-
 evaluated with an immunohistochemical assay in the IBCSG 
Central Pathology Laboratory. 
 To assess hormone receptor levels in archival formalin-fi xed 
and paraffi n-embedded tumor tissue specimens, sections were 
dewaxed, pretreated with 3% hydrogen peroxide for 5 minutes to 
block endogenous peroxidase activity, and then treated with 
0.001  M EDTA (pH 8.0) at 99 °C for 20 minutes to retrieve anti-
genicity. Sections were then incubated with specifi c primary 
mouse monoclonal antibodies against human ER (clone 1D5, 
1 : 100 dilution) or human PgR (clone 1A6, 1 : 800 dilution) (both 
obtained from Dako, Glostrup, Denmark) for 30 minutes at room 
temperature by use of an automatic immunostainer (Autostainer, 
Dako). Antibody – antigen complexes were subsequently visual-
ized with a high-sensitivity detection kit (EnVision+ System-
HRP; Dako) according to the manufacturer’s instructions. 
Peroxidase activity was visualized as a brown – black product by 
use of 3,3 ′ -diaminobenzidine and copper sulfate (Sigma Chemi-
cal Co, St Louis, MO) as the chromogen. 
 According to the recommendations for all IBCSG trials, we 
evaluated immunohistochemical results by the following proto-
col. 1) Tissue was checked for expected immunostaining of non-
neoplastic breast tissue (intense nuclear staining of at least a 
minor percentage of luminal epithelial cells) and lack of immu-
noreactivity of myoepithelial, stromal, and infl ammatory (if 
any) cells. 2) The staining pattern of the neoplastic component 
was evaluated at low or intermediate magnifi cation (×100 to 
×250) that took into account any biologically signifi cant hetero-
geneity of staining in different parts of the invasive tumor. Stain-
ing of the intraductal (or in situ) component was not considered. 
3) At higher magnifi cation (×400), any defi nite nuclear localiza-
tion of the immunostaining was assessed, without considering as 
specifi c any membrane or cytoplasmic staining. This nonspe-
cifi c staining may appear on occasion (especially when apocrine 
or squamous metaplasia is present), and it does not interfere 
with the specifi c nuclear staining of the hormone-responsive 
neoplastic cells. 4) For tumors with homogeneous staining 
throughout, at least 10 high-power fi elds (containing a minimum 
of 2000 invasive tumor cells) were randomly selected, and the 
number of cells showing nuclear immunostaining (irrespective 
of the staining intensity) was counted and compared with the 
total number of neoplastic cells. The results were recorded as an 
overall percentage. For tumors with biologically signifi cant 
staining heterogeneity, 10 high-power fi elds were selected to 
mirror the degree of staining heterogeneity. For example, if only 
20% of the invasive tumor area showed diffuse nuclear staining 
and the remaining tumor had only occasional (or no) immunore-
active cells, then only two high-power fi elds were counted in the 
former area and eight high-power fi elds were counted in the lat-
ter area. In tissues with about 10% immunoreactive cells, addi-
tional fi elds were counted and/or another pathologist checked 
the results. 
 Statistical Considerations 
 Extraction assay values (expressed as femtomoles per milli-
gram of cytosol protein) and immunohistochemistry values (ex-
pressed as the percentage of immunoreactive cells) were initially 
categorized as follows: 0 = none; 1 – 9 = low; 10 or more = high, 
with units corresponding to the assay used. The choice of cut 
points for the extraction assays refl ected the standard practice: a 
value of 10 fmol/mg of cytosol protein or more was used to indi-
cate a hormone receptor – positive status and a value of less than 
10 fmol/mg of cytosol protein was used to indicate a hormone 
receptor – negative status. The choice of cut point for the immu-
nohistochemical assay also refl ected the frequent practice: 10% 
immunoreactive cells or more were used to indicate a hormone 
receptor – positive status and less than 10% immunoreactive cells 
were used to indicate a hormone receptor – negative status, as well 
as evidence that the presence of any immunoreactive cells ap-
peared to indicate the endocrine responsiveness of the tumor 
 ( 11 ) . Thus for extraction assays, our dichotomization was nega-
tive (<10 fmol/mg of cytosol protein) and positive ( ≥ 10 fmol/mg 
of cytosol protein). For immunohistochemical assays, our dichot-
omization was absent (0% stained cells) and present (>0% stained 
cells) or was negative (<10% stained cells) and positive ( ≥ 10% 
stained cells). 
 Concordance denoted the number or percentage of tumors 
with the same classifi cation by the two assay methods. Agree-
ment denoted the chance-corrected concordance as measured by 
a  κ statistic, which was weighted ( κ w ) for ordinal hormone recep-
tor status variables and unweighted for dichotomous variables; 
95% confi dence intervals (CIs) were also calculated. 
 The primary outcome in both trials was disease-free survival, 
defi ned as the length of time from the date of randomization to 
any recurrent disease (including ipsilateral breast recurrence), 
the appearance of a second primary cancer (including contralat-
eral breast cancer), or death, whichever occurred fi rst. Hazard 
ratios (HRs) of recurrence or death (with corresponding 95% 
confi dence intervals) and log-rank tests were reported for com-
parisons of disease-free survival between treatment arms accord-
ing to hormone receptor status. Cox proportional hazards 
regression models were used to estimate hazard ratios and 95% 
confi dence intervals. To check assumptions of proportionality, 
curves of the log of the cumulative hazard versus time were 
 plotted and assessed visually to determine if the vertical shift 
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 between the curves was constant over time and by testing for an 
interaction term of treatment arm with time in the models. 
 The discriminatory ability of hormone receptor status to pre-
dict disease-free survival was evaluated separately according to 
treatment by use of the  c index  ( 28 , 29 ) . In this study, the  c index 
was interpreted as an estimate of the probability that, for two 
randomly chosen patients on the same treatment, the patient with 
a receptor-positive (or a receptor present) tumor will have longer 
disease-free survival than the patient with a receptor-negative (or 
a receptor absent) tumor. The  c indices were compared between 
assay methods by use of a  U statistic  ( 28 , 29 ) . Disease-free sur-
vival among patients whose tumors were concordant or discor-
dant by the two assay methods according to treatment were 
summarized by use of Kaplan – Meier plots. All statistical tests 
were two-sided, and  P values of less than .05 were considered to 
be statistically signifi cant. 
 All analyses were undertaken separately for the two trials. The 
data analysis used SAS version 9.1 (SAS Institute Inc, Cary, NC) 
and S-PLUS version 6.1 (Insightful Corp, Seattle, WA). 
 R ESULTS 
 Among the pre- and perimenopausal patients randomly 
 assigned to treatment in Trial VIII and the postmenopausal 
 patients randomly assigned to treatment in Trial IX, 571 (54%) of 
1063 patients and 976 (58%) of 1669 patients, respectively, had 
hormone receptor levels measured both locally by an  extraction 
assay and centrally by an immunohistochemical assay and were 
included in these analyses. The clinical characteristics of patients 
in this study and those of the trial cohorts were comparable, al-
though, in this analysis cohort, there were slightly fewer patients 
(123 [8%] of 1547 total patients) with tumors that were 0 – 1 cm 
in diameter than there were in the overall trial cohorts. Median 
duration of follow-up was 8.2 and 9.4 years in the Trials VIII and 
IX analysis cohorts, respectively; follow-up was more than 1.5 
years longer in these analysis cohorts than among patients who 
were not included in our study because patients in the analysis 
cohorts likely entered the trials earlier when only extraction as-
says were used to establish ER status at randomization. 
 The distributions of ER and PgR values are summarized in 
 Table 1 . Spearman’s rank correlation coeffi cients for the quanti-
tative values obtained by the two assay methods were .46 for ER 
and .61 for PgR among premenopausal patients and were .53 for 
ER and .61 for PgR among postmenopausal patients, indicating 
moderately strong positive associations between the quantitative 
assay values. 
 Concordance and Agreement 
 The classifi cation of tumors by hormone receptor status is pre-
sented in  Table 2 . The concordance and agreement of hormone 
receptor status as determined by extraction and immunohisto-
chemical assays are presented in  Table 3 . For the different hor-
mone receptor status variables in both pre- and postmenopausal 
patients, few tumors were classifi ed into the low category by im-
munohistochemical assay (1% – 9% of cells stained), and few tu-
mors were classifi ed as none (0 fmol/mg of cytosol protein) by 
extraction assays. Thus, the concordance of the three categories 
was in the range of 55% – 74% ( κ w , indicating agreement, ranged 
from 0.33 to 0.47). 
 In contrast, concordance and agreement were better for ex-
traction assay results dichotomized as negative or positive com-
pared with immunohistochemical assay results dichotomized as 
absent or present or as negative or positive; concordance ranged 
from 74% to 88% ( κ ranged from 0.48 to 0.66). For ER status, 
concordance and agreement were observed to be higher among 
postmenopausal patients (88%;  κ = 0.66) than among premeno-
pausal patients (81%;  κ = 0.53). However, concordance and 
agreement for PgR status were lower among postmenopausal pa-
tients (76%;  κ = 0.49) than among premenopausal patients (80%; 
 κ = 0.51), and concordance for ER status and PgR status was 
similar among premenopausal patients ( Fig. 1 ). 
 ER status from extraction assays indicated that 179 (32%) of 
562 tumors in premenopausal patients were ER negative and 231 
(24%) of 959 tumors in postmenopausal patients were ER nega-
tive. When the ER status of these ER-negative tumors was deter-
mined by immunohistochemical assay, 76 (42%) of the 179 
ER-negative tumors in premenopausal patients were ER present 
and 72 (31%) of the 231 ER-negative tumors in postmenopausal 
patients were ER present. Of 383 and 728 tumors in premeno-
pausal and postmenopausal patients, respectively, as determined 
by extraction assays to be ER positive, 30 (8%) and 44 (6%) were 
ER absent by immunohistochemical assay. Thus, approximately 
one-third of the 25% – 30% of patients who would not have been 
eligible for the trials after ER-negative tumors were deemed in-
eligible would have been considered as appropriate candidates 
for the trials according to immunohistochemical assay results, 
and approximately 10% of patients who were eligible according 
to extraction assay results would not have been considered as 
 appropriate trial candidates using immunohistochemical assays. 
 PgR results from extraction assays indicated that 162 (29%) 
of the 557 tumors in premenopausal patients were PgR nega-
tive and that 337 (37%) of the 919 tumors in postmenopausal 
patients were PgR negative. Among the 162 PgR-negative 
 Table 1.  Distributions of ER and PgR by extraction assays and by immunohistochemical (IHC) assay in premenopausal (Trial VIII) and postmenopausal (Trial IX) 
patients with lymph node – negative breast cancer * 
Receptor No. of patients
 Extraction assays, fmol/mg 
of cytosol protein
 
IHC, % of stained cells Spearman’s rank 
 correlation coeffi cientMedian (IQR) Range Median (IQR) Range
Premenopausal (Trial VIII)
  ER 562 19 (7 – 52) 0 – 600 71 (2 – 90) 0 – 100 .46
  PgR 557 39 (8 – 145) 0 – 7027 60 (0 – 90) 0 – 100 .61
Postmenopausal (Trial IX)
  ER 959 50 (10 – 188) 0 – 1815 90 (21 – 95) 0 – 100 .53
  PgR 919 19 (4 – 100) 0 – 2564 15 (0 – 75) 0 – 100 .61
 * ER = estrogen receptor; PgR = progesterone receptor; IQR = interquartile range. 
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 tumors in premenopausal patients, 58 (36%) were PgR present 
by immunohistochemical assay, and among the 337 PgR-
 negative tumors in postmenopausal patients, 113 (34%) were 
PgR present by immunohistochemical assay. Among the 395 
and 582 PgR-positive tumors by extraction assays in pre-
menopausal and postmenopausal patients, respectively, 53 
(13%) and 105 (18%) were PgR absent by immunohisto-
chemical assay. 
 Among the few tumors staining ER low by immunohis to-
chemical assay, six (40%) of the 15 such tumors in  premenopausal 
patients and nine (50%) of the 18 such tumors in postmenopausal 
patients were ER positive by the extraction assay. Among tumors 
staining PgR low by immunohistochemical assay, 20 (59%) of 
the 34 such tumors in premenopausal patients and 53 (60%) of 
the 89 such tumors in postmenopausal patients were PgR pos -
itive by the extraction assay. This fi nding suggests that it was 
 reasonable to consider tumors classifi ed as hormone receptor low 
by immunohistochemical assay as also endocrine responsive. 
Thus, in subsequent analyses, we focused on immunohisto chemical 
assay values that were dichotomized as absent versus present and 
 Table 2.  Classifi cation of tumors by extraction assays (fmol/mg of cytosol protein) and by immunohistochemical (IHC) assay (% of stained cells) in 
premenopausal (Trial VIII) and postmenopausal (Trial IX) patients with lymph node – negative breast cancer * 
 IHC
Absent  Present  
Trial Receptor Extraction assay None (0) Low (1 – 9) High ( ≥ 10) Total
Premenopausal (Trial VIII) ER Negative
  None (0) 21 (3.7) 3 (0.5) 8 (1.4) 32 (5.7)
  Low (1 – 9) 82 (14.6) 6 (1.1) 59 (10.5) 147 (26.2)
Positive
  High ( ≥ 10) 30 (5.3) 6 (1.1) 347 (61.7) 383 (68.1)
Total 133 (23.7) 15 (2.7) 414 (73.7) 562 (100)
PgR Negative
  None (0) 24 (4.3) 2 (0.4) 10 (1.8) 36 (6.5)
  Low (1 – 9) 80 (14.4) 12 (2.2) 34 (6.1) 126 (22.6)
Positive
  High ( ≥ 10) 53 (9.5) 20 (3.6) 322 (57.8) 395 (70.9)
Total 157 (28.2) 34 (6.1) 366 (65.7) 557 (100)
Postmenopausal (Trial IX) ER Negative
  None (0) 26 (2.7) 1 (0.1) 10 (1.0) 37 (3.9)
  Low (1 – 9) 133 (13.9) 8 (0.8) 53 (5.5) 194 (20.2)
Positive
  High ( ≥ 10) 44 (4.6) 9 (0.9) 675 (70.4) 728 (75.9)
Total 203 (21.2) 18 (1.9) 738 (77.0) 959 (100)
PgR Negative
  None (0) 55 (6.0) 9 (1.0) 16 (1.7) 80 (8.7)
  Low (1 – 9) 169 (18.4) 27 (2.9) 61 (6.6) 257 (28.0)
Positive
  High ( ≥ 10) 105 (11.4) 53 (5.8) 424 (46.1) 582 (63.3)
  Total 329 (35.8) 89 (9.7) 501 (54.5) 919 (100)
 * ER = estrogen receptor; PgR = progesterone receptor. 
 Table 3.  Concordance and agreement of hormone receptor status between the extraction assay and the immunohistochemical (IHC) assay and 
corresponding κ statistic (95% CI) by categorization * 
 Extraction assay versus IHC † 
Receptor None/low/high versus none/low/high Negative/positive versus negative/positive Negative/positive versus absent/present
Premenopausal (Trial VIII)
  ER status (n = 562)
   No. concordant (%) 374 (67) 459 (82) 456 (81)
   κ (95% CI) 0.41 (0.35 to 0.47) 0.56 (0.48 to 0.63) 0.53 (0.46 to 0.61)
  PgR status (n = 557)
   No. concordant (%) 358 (64) 440 (79) 446 (80)
   κ (95% CI) 0.37 (0.31 to 0.43) 0.52 (0.44 to 0.59) 0.51 (0.43 to 0.59)
Postmenopausal (Trial IX)
  ER status (n = 959)
   No. concordant (%) 709 (74) 843 (88) 843 (88)
   κ (95% CI) 0.47 (0.42 to 0.51) 0.66 (0.61 to 0.72) 0.66 (0.60 to 0.71)
  PgR status (n = 919)
   No. concordant (%) 506 (55) 684 (74) 701 (76)
   κ (95% CI) 0.33 (0.29 to 0.38) 0.48 (0.42 to 0.53) 0.49 (0.43 to 0.55)
 * ER = estrogen receptor; PgR = progesterone receptor; CI = confi dence interval.  κ statistics were weighted for ordinal  hormone receptor status and unweighted for 
dichotomous hormone receptor status. 
 † None, low, and high are 0, <10, and  ≥ 10, respectively, with appropriate units of measure; negative versus positive are <10 versus  ≥ 10; and absent versus present 
are 0 versus >0. For the extraction assay, units are fmol/mg of cytosol protein. For IHC, units are percentage of stained cells. 
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extraction assay values that were dichotomized standardly as 
negative versus positive at a cut point of 10 fmol/mg of cytosol 
protein. 
 Trial Results 
 The forest plot in  Fig. 2 summarizes evaluations of outcomes 
for Trials VIII and IX that are based on the patients included in 
this analysis. For each trial, disease-free survival was compared 
between treatment arms according to hormone receptor status, 
which was determined by extraction assays (negative or positive) 
and by an immunohistochemical assay (absent or present). Haz-
ard ratios of recurrence or death and corresponding 95% confi -
dence intervals are presented. 
 In Trial VIII, we observed remarkably similar treatment com-
parison results between the two assay methods among subgroups 
of premenopausal patients defi ned by ER status, i.e., the esti-
mated hazard ratios and 95% confi dence intervals comparing 
treatments among the ER-negative subgroup defi ned by extrac-
tion assays are virtually identical to the those among ER-absent 
 
 Fig. 1.  Concordance of hormone receptor status as determined by extraction 
assays (ExA) and immunohistochemical (IHC) assays, for premenopausal 
and perimenopausal (Trial VIII) and postmenopausal (Trial IX) patients. For 
ExA, the cut-point values for negative versus positive tumors were <10 or  ≥ 10 
fmol/mg of cytosol protein. For IHC, the cut-point values for absent versus 
present tumors were 0% or >0% immunoreactive cells. The discordance, shown 
at the top of the bars, ranged from 12.0% to 23.6%. ER = estrogen receptor; 
PgR = progesterone receptor. 
 Fig. 2.  Disease-free survival. Single-agent 
endocrine therapy was compared with 
chemotherapy, with or without endocrine 
therapy for hormone receptor status, as 
determined by extraction assays (ExA) 
and by immunohistochemi cal (IHC) 
assays for premenopausal (Trial VIII) 
and postmenopausal (Trial IX) patients 
included in this study. Hazard ratios of 
recurrence or death are presented. For 
ExA, the cut-point values for negative 
versus positive tumors were <10 or  ≥ 10 
fmol/mg of cytosol protein. For IHC, the 
cut-point values for absent versus present 
tumors were 0% or >0% immunoreactive 
cells. Results were remarkably consistent, 
with the exception of comparisons within 
the premenopausal progesterone receptor 
(PgR) subgroups, which are enclosed in 
a  dashed box .  P values were calculated 
from two-sided log-rank tests. Pts = 
patients; CI = confi dence interval; CT = 
chemotherapy; ET = endocrine therapy; 
CMF = cyclophosphamide, methotrexate, 
and fl uorouracil chemotherapy. 
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subgroup defi ned by immunohistochemical assay (e.g., for the 
comparison CMF versus goserelin: ER-negative HR = 0.60, 95% 
CI = 0.30 to 1.17; ER-absent HR = 0.61, 95% CI = 0.30 to 1.26). 
In contrast, we observed different results among subgroups de-
fi ned by PgR status that were determined by the two assay meth-
ods, especially in comparisons that included goserelin. In the 
PgR-absent subgroup as defi ned by immunohistochemical assay, 
the decreased hazard of recurrence or death in the CMF-alone 
arm or the CMF – goserelin arm, as compared with that in the 
 goserelin-alone arm, was more striking (for the comparison CMF 
versus goserelin, HR = 0.62, 95% CI = 0.32 to 1.19; for the com-
parison CMF – goserelin versus goserelin, HR = 0.46, 95% CI = 
0.23 to 0.90); in the PgR-present subgroup defi ned by immuno-
histochemical assay, the ratios of hazards of recurrence or death 
were not statistically different from unity (for the comparison of 
CMF versus goserelin, HR = 0.92, 95% CI = 0.55 to 1.54; for the 
comparison CMF – goserelin versus goserelin, HR = 0.99, 95% 
CI = 0.60 to 1.65). 
 These observations were confi rmed in an assessment of how 
well ER status and PgR status predicted disease-free survival 
within a given treatment arm ( Table 4 ) and in a comparison of 
hormone receptor status as determined by extraction assays and 
by immunohistochemical assay. Among patients treated with 
goserelin alone, ER status as determined by extraction assays 
and that determined by immunohistochemical assay had similar 
discriminatory ability ( c index = 0.54 and 0.56, respectively; 
 P = .87). However, the discriminatory ability of PgR status as 
determined by immunohistochemical assay was statistically 
 signifi cantly better than that determined by extraction assays 
( c index = 0.60 and 0.51, respectively;  P = .003), with PgR sta-
tus determined by extraction assays having little ability to pre-
dict disease-free survival among goserelin-treated patients. To 
illustrate these results, disease-free survival among patients ran-
domly assigned to the goserelin-alone arm was summarized 
( Fig. 3 ) for ER status and PgR status as classifi ed by the two as-
say methods. Among the 15 patients whose PgR status was PgR 
present by the immunohistochemical assay and PgR negative by 
the extraction assay ( Fig. 3, B ), only one patient experienced a 
recurrence or death; whereas, among the 15 patients whose PgR 
status was PgR absent by the immunohistochemical assay and 
PgR positive by the extraction assay, eight patients experienced 
recurrence or death ( Fig. 3, B ). 
 Among postmenopausal patients in Trial IX, similar esti-
mates of hazard ratios were obtained when the two assay meth-
ods were used to determine hormone receptor status, and the 
same conclusions would be reached — i.e., adjuvant CMF in ad-
dition to tamoxifen increased disease-free survival compared 
with tamoxifen alone among patients with ER-negative tumors 
but not among patients with ER-positive tumors ( Fig. 2 ). A 
similar pattern was found for PgR status, although results that 
were based on PgR status appeared more discrepant. Among 
patients on the tamoxifen-alone arm, ER status and PgR status 
as determined by extraction assay or by an immunohistochem-
ical assay could predict response to tamoxifen, with  c index 
values ranging from 0.55 to 0.58, but values were not statisti-
cally signifi cantly different between assay methods (for ER 
status,  P = .37; for PgR status,  P = .23;  Table 4 ). As an illustra-
tion, disease-free survival among patients in the tamoxifen-
alone arm was summarized according to ER status and PgR 
status as classifi ed by both assay methods ( Fig. 3 ). Disease-free 
survival appeared slightly, although not statistically signifi -
cantly, better for patients whose ER status was ER present by 
an immunohistochemical assay and ER negative by the extrac-
tion assay than for patients whose ER status was ER absent by 
an immunohistochemical assay and ER positive by the extrac-
tion assay ( Fig. 3, C ). 
 D ISCUSSION 
 In this re-evaluation of data from two IBCSG randomized 
clinical trials of adjuvant therapy in premenopausal (Trial VIII) 
and postmenopausal (Trial IX) patients with lymph node – nega-
tive breast cancer, conclusions that were based on ER status de-
termined by immunohistochemical assay performed at a central 
laboratory confi rmed those that were based on ER status deter-
mined by extraction assays performed at local pathology labora-
tories (i.e., premenopausal and postmenopausal women with 
ER-negative, lymph node – negative breast cancer benefi ted [in 
terms of better disease-free survival] from the  addition of adjuvant 
chemotherapy to endocrine therapy, whereas if their cancer was 
ER positive, postmenopausal women obtained no benefi t from 
the combination treatment compared with endocrine therapy 
alone and for premenopausal women the use of combination 
treatment or endocrine therapy alone required further study). 
When disease-free survival was evaluated according to PgR 
status of the primary tumor, which was not examined in the 
 primary trial analyses, PgR status that was determined by an 
 Table 4.  Evaluation of the discriminatory ability ( c index) of hormone receptor 
status variables determined by extraction assays and by immunohistochemical 
(IHC) assay separately by treatment * 
Receptor
Extraction assay, 
negative versus 
positive † 
IHC, 
absent versus 
present †  P value ‡ 
Premenopausal (Trial VIII)
  Goserelin (n = 182)
   ER 0.54 0.56 .87
   PgR 0.51 0.60 .003
  CMF (n = 193)
   ER 0.49 0.53 .32
   PgR 0.53 0.55 .83
  CMF  → goserelin (n = 196)
   ER 0.48 0.50 .49
   PgR 0.48 0.50 .87
Postmenopausal (Trial IX)
  Tamoxifen (n = 491)
   ER 0.56 0.58 .37
   PgR 0.55 0.56 .23
  CMF  → tamoxifen (n = 485)
   ER 0.49 0.50 .47
   PgR 0.52 0.54 .83
 * ER = estrogen receptor; PgR = progesterone receptor; CMF = cyclophospha-
mide, methotrexate, and fl uorouracil chemotherapy. The  c index estimates the 
probability that, of two randomly chosen patients receiving the same treatment, 
the patient with a receptor-positive tumor will have longer disease-free survival 
than the patient with a receptor-negative tumor (or for IHC, receptor-present 
versus receptor-absent tumor). Values of  c index that are near to 0.5 indicate that 
receptor status is no different than chance in determining which patient will have 
longer disease-free survival, and values that are near to 0 or 1 indicate that re-
ceptor status virtually always determine which patient has longer disease-free 
survival. 
 † Extraction assays negative versus positive are <10 versus  ≥ 10 fmol/mg of 
cytosol protein, respectively; IHC assays absent versus present are 0 versus >0% 
of immunoreactive cells, respectively. 
 ‡ The  P value that compared the  c index of extraction assay result of negative or 
positive with that of IHC result of absent or present is from a two-sided  U statistic. 
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 immunohistochemical assay could predict response to endocrine 
therapy better than that determined by extraction assays, particu-
larly among pre- and perimenopausal patients. These results pro-
vide confi dence in the use of steroid hormone receptor status 
determined by immunohistochemical assay to select adjuvant 
treatment, even though the clinical trials on which these  evidence-
based recommendations were established had determined hor-
mone receptor status by locally performed extraction assays, 
which are expected to have a discordance of 10% – 30% with re-
spect to immunohistochemical assay. 
 We investigated data from two randomized clinical trial 
 populations of patients with lymph node – negative, early-stage 
invasive breast cancer. The trial populations were pre- and peri-
menopausal patients and postmenopausal patients who 
 underwent similar well-defi ned treatment strategies to evaluate 
the combination of chemoendocrine therapy compared with en-
docrine therapy alone. Only two other studies  ( 14 , 30 ) used ran-
domized clinical trial populations who received adjuvant 
therapy, but the cohorts of patients with lymph node – positive 
disease were smaller in both studies than those in Trials VIII and 
IX. In the IBCSG trial populations of patients with lymph node –
 negative breast cancer, immunohistochemical assay – determined 
hormone receptor status and extraction assay – determined status 
had rates of concordance and agreement that were consistent 
with those previously reported  ( 6 – 14 ) , and we confi rmed that 
immunohistochemical assay – determined hormone receptor sta-
tus was a valid discriminator of endocrine responsiveness and 
chemosensitivity. 
 In particular, among pre- and perimenopausal patients in Trial 
VIII, the benefi t of increased disease-free survival associated 
with CMF followed by goserelin, compared with goserelin 
alone, was most clearly evident among PgR-absent tumors, as 
determined by immunohistochemical assay. In contrast, among 
postmenopausal patients in Trial IX, ER status demonstrated 
the benefi t of increased disease-free survival associated with 
 adjuvant CMF among patients with ER-negative (or ER-absent) 
tumors, regardless of assay method. Colleoni et al.  ( 31 ) also 
found that PgR status was more predictive of response to periop-
erative chemotherapy than ER status among premenopausal pa-
tients with lymph node – negative disease, whereas ER status was 
more predictive of response than PgR status among postmeno-
pausal patients. 
 When we compared the results of locally assessed extraction 
assays with those of centrally assessed immunohistochemical as-
say in these trial populations of patients with lymph node – nega-
tive disease, the immunohistochemical assay appeared to increase 
the fraction of ER-present and PgR-present tumors in both pre- 
and perimenopausal patients and in postmenopausal patients, 
most likely because of the overall higher sensitivity of the im-
munohistochemical assay. The fraction of tumors that scored 
positive by use of extraction assays and absent by use of an im-
munohistochemical assay was much higher for PgR levels than 
 Fig. 3.  Kaplan – Meier estimates of disease-free 
survival according to concordance of hormone 
receptor status determined by extraction assay (ExA) 
and by immunohistochemical (IHC) assay.  Black 
lines indicate discordant assay results;  shaded 
lines indicate concordant assay results.  A ) Estrogen 
receptor (ER) status among premenopausal patients 
on the goserelin-only arm of Trial VIII. The numbers 
of patients at risk at times 0, 5, and 8 years were 23, 
17, and 10 for those with ExA-negative and IHC-
present tumors; 10, 6, and 5 for those with ExA-
positive and IHC-absent tumors; 36, 25, and 13 for 
those with ExA-negative and IHC-absent tumors; 
and 110, 74, and 39 for those with ExA-positive and 
IHC-present tumors. Estimates of 5-year disease-
free survival were 78% (95% confi dence interval 
[CI] = 55% to 90%), 60% (95% CI = 25% to 83%), 
69% (95% CI = 52% to 82%), and 82% (95% CI = 
73% to 88%), respectively.  B ) Progesterone receptor 
(PgR) status among premenopausal patients on the 
goserelin-only arm of Trial VIII. The numbers of 
patients at risk at times 0, 5, and 8 years were 15, 15, 
and 7 for those with ExA-negative and IHC-present 
tumors; 15, 9, and 3 for those with ExA-positive and 
IHC-absent tumors; 37, 25, and 15 for those with 
ExA-negative and IHC-absent tumors; and 107, 70, 
and 40 for those with ExA-positive and IHC-present 
tumors. Estimates of 5-year disease-free survival 
were 100% (95% CI = 78% to 100%), 60% (95% 
CI = 32% to 80%), 68% (95% CI = 50% to 80%), 
and 82% (95% CI = 73% to 88%), respectively. 
 C ) ER status among postmenopausal patients on 
the tamoxifen-only arm of Trial IX. The numbers of 
patients at risk at times 0, 5, and 8 years were 37, 24, 
and 17 for those with ExA-negative and IHC-present 
tumors; 25, 13, and 11 for those with ExA-positive and IHC-absent tumors; 82, 
49, and 31 for those with ExA-negative and IHC-absent tumors; and 340, 255, 
and 162 for those with ExA-positive and IHC-present tumors. Estimates of 
5-year disease-free survival were 78% (95% CI = 61% to 89%), 64% (95% CI = 
42% to 79%), 62% (95% CI = 51% to 72%), and 86% (95% CI, 82% to 89%), 
respectively.  D ) PgR status among postmenopausal patients on the tamoxifen-
only arm of Trial IX. The numbers of patients at risk at times 0, 5, and 8 years 
were 57, 36, and 24 for those with ExA-negative and IHC-present tumors; 
53, 30, and 22 for those with ExA-positive and IHC-absent tumors; 116, 78, 
and 50 for those with ExA-negative and IHC-absent tumors; and 242, 184, and 
114 for those with ExA-positive and IHC-present tumors. Estimates of 5-year 
disease-free survival were 77% (95% CI = 63% to 86%), 73% (95% CI = 58% 
to 83%), 69% (95% CI = 60% to 76%), and 87% (95% CI = 82% to 91%), 
respectively. 
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for ER levels in both trials, suggesting that extraction  assays 
were more likely to yield false-positive results for PgR status 
than for ER status. This result appeared to be especially true 
among pre- and perimenopausal patients because, when extrac-
tion assays were used, the fraction of patients with PgR-positive 
tumors was greater than the fraction of patients with ER-positive 
tumors, a result that is at variance with the current knowledge on 
the coordinate expression of the two receptors  ( 32 ) . The false-
positive results for PgR status as determined by extraction assays 
may explain its inability to predict disease-free survival among 
pre- and perimenopausal patients treated with endocrine therapy 
alone and its inability to demonstrate disease-free survival bene-
fi t of chemoendocrine therapy compared with endocrine therapy 
alone in PgR-negative tumors. These abilities emerged clearly 
when we reassessed PgR status among pre- and perimenopausal 
patients by immunohistochemical assay. 
 The main advantages of immunohistochemical assays com-
pared with extraction assays are that immunohistochemical as-
says are easier and quicker to perform and may be performed 
on very small tumors or tumor specimens, such as those ob-
tained by fi ne-needle aspiration biopsy or core biopsy examina-
tions. Immunohistochemical assays allow precise determination 
of hormone receptor status at the individual cell level, by  taking 
into account only the neoplastic cells of the invasive  component 
of the tumor, and thereby accommodate the heterogeneity of 
hormone receptor expression in tumors, which cannot be eval-
uated by extraction assays. Extraction assays, in contrast, gen-
erally provide an overall score for the  entire cell population of 
the tumor tissue, including non-neoplastic cells and in situ 
components of the tumor, and thus may lead to false-positive or 
false-negative fi ndings, depending on the relative proportions 
of truly invasive tumor cells and other cell types in the tumor 
tissue. Extraction assays also quantitatively evaluate the hor-
mone receptor content of the sample, which may be more dif-
fi cult to achieve by immunohistochemical assay. In fact, the 
quantitative or semiquantitative assessment of the percentage 
of immunoreactive cells may not be truly representative of the 
quantitative differences in hormone receptor content of differ-
ent tumors. Both intensity of staining and number of immuno-
stained cells in different tumor samples may be affected by 
preanalytical (e.g., type and length of fi xation) and analytical 
(e.g., type and concentration of the immunohistochemical re-
agents or the immunostaining protocol) variables and by inter-
pretative bias. As a consequence, intra- and interlaboratory 
reproducibility of the results of immunohistochemical assays 
for hormone receptor levels may reduce the predictive power 
of hormone receptor status and thus affect the choice of the 
most appropriate therapeutic intervention. It is essential that 
the reproducibility of immunohistochemical assay results be 
substantially improved by active participation of all involved 
laboratories in quality assurance and quality control programs 
and that standardized procedures, such as those used by IBCSG 
and also used in this study, be adopted to satisfy the continual 
need for accurate evaluation of receptor status. The standa rd-
ized approach to evaluation and immunostaining used by 
IBCSG minimized interlaboratory technical variations and 
 underscores the value of tissue collection and central review of 
hormone receptors as part of randomized clinical trials evaluating 
adjuvant systemic therapies for breast cancer. 
 When interpreting the results of this study, certain limitations 
should be taken into account. First, we were unable to determine 
whether a cut point of 1% or more or of 10% or more stained 
cells in immunohistochemical assays was more concordant with 
tumors classifi ed as ER positive ( ≥ 10 fmol/mg of cytosol protein) 
by extraction assays because too few tumors were classifi ed into 
the ER low category by immunohistochemical assay (1% – 9% of 
cells stained). Second, the small numbers of tumors with discor-
dant classifi cation prevented direct comparisons of disease-free 
survival between patients whose tumors were hormone receptor 
absent by immunohistochemical assay and positive by extraction 
assay with patients whose tumors were hormone receptor present 
by immunohistochemical assay and negative by extraction assay. 
Finally, about 20% of patients randomly assigned to treatment in 
Trials VIII and IX did not have archival tumor material available 
for hormone receptor evaluation, though the clinical characteris-
tics of patients included in this study and those of the overall trial 
cohorts were comparable, with the exception that there were 
slightly fewer patients with tumors that were 1 cm or less in di-
ameter in this study. 
 Despite the 10% – 30% discordance in steroid hormone recep-
tor status determined by immunohistochemical assay versus 
extraction assays, on average in this population of lymph 
node – negative invasive breast cancers, the presence or absence 
of ER determined by an immunohistochemical assay confi rmed 
randomized clinical trial results that were based on ER status de-
termined by extraction assays. PgR status determined by immu-
nohistochemical assay improved the ability of PgR to predict 
response to endocrine therapy, particularly among pre- and peri-
menopausal patients. 
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